Protein Kinase Inhibitors: all 15,278 studies that test it

Page 110 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaActive, not recruitingNCT02940301Phase 2
• Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid TumoursWithdrawnNCT02939846Phase 1
• A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular CarcinomaWithdrawnNCT02939807Phase 2
• A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological MalignanciesTerminatedNCT02937675Phase 1/2
• Study for MR Formulation of PF-06650833 in Healthy Adult Japanese SubjectsCompletedNCT02936154Phase 1
• Capecitabine and Lenvatinib With External Radiation in Rectal AdenocarcinomaCompletedNCT02935309Phase 1
• Ribociclib (LEE011) Rollover Study for Continued AccessActive, not recruitingNCT02934568Phase 2
• Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT02934256Phase 2
• Ribociclib (LEE011) in Preoperative Glioma and Meningioma PatientsActive, not recruitingNCT02933736Early Phase 1
• Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentActive, not recruitingNCT02932280Phase 1/2
• A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute LeukemiaCompletedNCT02930109Phase 1/2
• Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLCStatus unknownNCT02929290Phase 1
• Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With GlioblastomaStatus unknownNCT02928575Phase 2
• A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial LesionsStatus unknownNCT02927340Phase 2
• Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid TumorsCompletedNCT02926768Phase 1
• The Effect of Azithromycin on BCT197 Exposure in Healthy Male VolunteersCompletedNCT02926326Phase 1
• Regorafenib in Relapsed GlioblastomaCompletedNCT02926222Phase 2
• A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.CompletedNCT02925104Phase 1
• Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney ImpairmentCompletedNCT02923947Phase 1
• Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.CompletedNCT02922777Phase 1
• Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)Status unknownNCT02919371Phase 1/2
• An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedNCT02917993Phase 1/2
• 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patientsActive, not recruitingNCT02917720Phase 2
• Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With MyelofibrosisCompletedNCT02917096Phase 1
• PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast CancerStatus unknownNCT02917005Phase 2
• Kanitinib in Treating Patients With Advanced Solid TumorsCompletedNCT02916095Phase 1
• A Clinical Trial of Patients With MelanomaWithdrawnNCT02915666Phase 1
• Lenvatinib and Capecitabine in Patients With Advanced MalignanciesWithdrawnNCT02915172Phase 1
• Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC PatientsCompletedNCT02914990Phase 1
• A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisCompletedNCT02914535Phase 3
• Safety and Activity of SNX-5422 Plus Ibrutinib in CLLWithdrawnNCT02914327Phase 1
• A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male SubjectsCompletedNCT02913716Phase 1
• Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia PatientsStatus unknownNCT02912754Phase 1/2
• Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal CancerTerminatedNCT02910843Phase 1
• Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaActive, not recruitingNCT02910700Phase 2
• Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaCompletedNCT02909777Phase 1
• Relieving Chronic Itch: Oral MedicationWithdrawnNCT02909569Phase 2
• Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLCCompletedNCT02908750Phase 1
• Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT02906397Phase 1
• Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal CancerCompletedNCT02906059Phase 1
• Volasertib Combined With Induction Chemotherapy in Acute Myeloid LeukemiaWithdrawnNCT02905994Phase 1
• Palbociclib in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02905318Phase 2
• Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902042Phase 1/2
• Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902029Phase 2
• Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell LymphomasCompletedNCT02900716Phase 1
• A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
• A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerStatus unknownNCT02897479Phase 2
• First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001CompletedNCT02896231Phase 1
• Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 StudyStatus unknownNCT02894645Phase 4
• Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2
• Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy SubjectsStatus unknownNCT02892370Phase 1
• Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell LymphomasCompletedNCT02891590Phase 1
• Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the HostCompletedNCT02891395Phase 2
• Dasatinib Holiday for Improved TolerabilityCompletedNCT02890784Phase 3
• Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTsCompletedNCT02889328Phase 2
• Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic LeukemiaCompletedNCT02888990Phase 2
• EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLCStatus unknownNCT02886195Phase 3
• Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL GeneStatus unknownNCT02885766Phase 1/2
• Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric CarcinomaStatus unknownNCT02884453Phase 2
• First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR MutationStatus unknownNCT02883543Phase 3
• Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate CancerActive, not recruitingNCT02881242Phase 2
• Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA CapsuleCompletedNCT02877225Phase 1
• Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other TumorsCompletedNCT02876224Phase 1
• Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor ComplexWithdrawnNCT02876081Phase 2
• Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/CisplatinStatus unknownNCT02875457Phase 3
• Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell LymphomasWithdrawnNCT02875002Phase 1
• Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human TrialCompletedNCT02874989Phase 1
• ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following RadiotherapyTerminatedNCT02874651Phase 2
• Pharmacokinetics of Dabrafenib in Subjects With Hepatic ImpairmentTerminatedNCT02873650Phase 1
• BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedNCT02872259Phase 1/2
• Donafenib for Previously Treated Metastatic Colorectal CancerCompletedNCT02870582Phase 3
• Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid CancerCompletedNCT02870569Phase 2
• Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian CancerCompletedNCT02867956Phase 2
• Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical ResectionTerminatedNCT02867280Phase 3
• Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or EndometriumStatus unknownNCT02866370Phase 2
• Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease ProgressionCompletedNCT02863718Phase 3
• A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic CancerStatus unknownNCT02863367Phase 2
• Nintedanib as Switch Maintenance Treatment of Pleural Malignant MesotheliomaTerminatedNCT02863055Phase 2
• Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaWithdrawnNCT02861040Phase 1
• Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14CompletedNCT02860936Phase 2
• A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic CancerCompletedNCT02860780Phase 1
• Topical Everolimus in Patients With Tuberous Sclerosis ComplexWithdrawnNCT02860494Phase 2/3
• A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT02859948Phase 1
• EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT02859077Phase 3
• Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic CarcinomaCompletedNCT02859012Phase 2
• Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain SyndromeStatus unknownNCT02858453Phase 3
• A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedNCT02857998Phase 1
• A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired SubjectsCompletedNCT02857868Phase 1
• Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14CompletedNCT02857712Phase 2
• A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerCompletedNCT02857270Phase 1
• Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)WithdrawnNCT02856867Phase 2
• Trial Of Pembrolizumab And NintedanibCompletedNCT02856425Phase 1
• Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy VolunteersCompletedNCT02853643Phase 1
• Pharmacokinetics of Dabrafenib in Subjects With Renal ImpairmentCompletedNCT02852239Phase 1
• Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma PatientsTerminatedNCT02850744Phase 2
• Apatinib and Irinotecan in Treating Patients With Recurrent High-grade GliomaStatus unknownNCT02848794Phase 1/2
• Randomized Trial of Crenolanib in Subjects With D842V Mutated GISTStatus unknownNCT02847429Phase 3
• Study of Abemaciclib in Dedifferentiated LiposarcomaActive, not recruitingNCT02846987Phase 2
• Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR SignalingWithdrawnNCT02846766Phase 2

← Protein Kinase Inhibitors overview